跳至主要内容
临床试验/EUCTR2005-003195-38-DE
EUCTR2005-003195-38-DE进行中(未招募)1 期

Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal osteoporosis without vertebral fractures - SPIMOS 3D

Center for Muscle and Bone Research of the Charité Universitaetsmedizin Berlin0 个研究点目标入组 62 人开始时间: 2005年9月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Age between 60 and 75 years
  • Menopause > 5 years
  • Measurable BMD of the spine and hip by DXA (e.g. no metal devices or severe degenerative changes)
  • BMD of spine (L1 – L4) or hip = -2.0 and > -3.5 SD T-score measured by DXA
  • Patients who, in the opinion of the investigator, are able and willing to comply with the protocol for its duration
  • Written informed consent
  • 3DpQCT measurable at both skeletal sites, distal tibia and radius
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • spine or hip BMD = -3,5 SD T-Score measured by DXA
  • Vertebral fractures
  • Multiple (>2) low trauma peripheral fractures
  • Employees of the Centre of Muscle and Bone Research, or their relatives
  • Medical history
  • Disease/disorder known to influence bone metabolism: chronic gastrointestinal or liver disease, chronic alcoholism, severe malabsorption syndrome, primary hyperpara-thyroidism, Paget's disease of bone, histologically documented osteomalacia, or documented active thyroid disease without treatment
  • History of major upper gastro-intestinal (GI) disease
  • Diagnosed malignant disease within the previous 10 years (except successfully resected basal cell cancer)
  • Previous medication
  • Previous treatment with a bisphoshonate at any time
  • Treatment with fluoride for osteoporosis (dose greater than 10 mg/day) within the last 12 months, or for more than 2 years (total duration)
  • Treatment with PTH and similar agents or strontium ranelate at any time
  • Treatment with other drugs affecting bone metabolism within the last 6 months
  • ?Chronic systemic corticosteroid treatment
  • ?estrogens, progestins, SERMs, anabolic steroids, active Vit. D analogs/metabolites, calcitonin)
  • ?Calcineurin inhibitors (e.g. cyclosporine, tacrolimus) or methotrexate
  • Serum total Ca 2+ < 2.2 mmol/l or > 2.6 mmol/l
  • Vitamin D deficiency (serum 25-hydroxy vitamin D < 12 ng/ ml
  • ALT above triple upper limit of normal range
  • Renal impairment (serum creatinine > 210 µmol/l)
  • Contra indications for ibandronate, calcium or vitamin D

研究者

发起方
Center for Muscle and Bone Research of the Charité Universitaetsmedizin Berlin

相似试验